VerityRank
AstraZeneca PLC
Brand & Manufacturer VerifiedUnited Kingdom

AstraZeneca PLC

AstraZeneca

AstraZeneca PLC reinforced its status as the most glocalized of the pharmaceutical super-majors in FY2025, generating $58.7 billion in revenue (+8% at constant exchange rates) powered by simultaneous strength in oncology, CVRM, and rare disease portfolios. The company's 2025 performance was marked by extraordinary pipeline productivity: 16 positive Phase III readouts and 43 major regulatory approvals across global jurisdictions. AstraZeneca's China strategy has evolved beyond market access into deep industrial integration—a $15 billion commitment through 2030 aims to transform its Chinese operations into a global hub for cell therapy and radioconjugate manufacturing. The $1.2 billion upfront licensing deal (potential $18.5 billion total) for CSPC's preclinical GLP-1/GIP dual-agonist catapulted AstraZeneca into the metabolic disease arena. With 31 manufacturing sites across 16 countries, an independently operable dual-source supply system isolating Chinese and Western supply chains, and 80,000 employees (20,000+ in China alone), AstraZeneca has constructed a geopolitical risk-hedged operating model that competitors admire but struggle to replicate.

Strengths: The China dual-supply-chain strategy—maintaining completely independent, self-sufficient manufacturing and distribution networks in China and the West—represents the most sophisticated geopolitical risk management framework in the industry, insulating AstraZeneca from US-China decoupling scenarios that threaten competitors' single-source dependencies. Pipeline breadth across oncology (Tagrisso, Imfinzi, Enhertu partnership), CVRM (Farxiga), respiratory, rare disease, and now metabolic disease provides therapeutic diversification matched only by Roche and J&J. The 2025 productivity surge (16 positive Phase IIIs, 43 approvals) demonstrates clinical development execution at peak efficiency.

Weaknesses: The 2023-2024 China senior executive importation and data compliance scandal—though settled—left reputational scarring and elevated compliance oversight costs that continue to weigh on China operational agility. The CSPC obesity drug deal, while strategically necessary, came at an extraordinarily rich price for a Phase I asset, creating substantial binary risk. AstraZeneca's late entry into the GLP-1 metabolic market means competing against Lilly and Novo Nordisk's deeply entrenched physician prescribing habits and patient brand loyalty.
Read More
United KingdomFounded 199980,000+$58,739M31 core manufacturing bases… / 100
Listed onNYSEAZNLSE
Last updated: 2026-11-19 16:00 ET·By VerityRank Research Team·Methodology

Listed market data

AZN · NYSE · weeklyHistory →
Market cap
$287 B
Share price
USD 175.34
1Y change
+14.0%
Recent change
-1.9%

11-19

Since first close
×17.4

from 1993

Revenue (TTM)
$61.4 B
After-hoursUSD 175.00-0.23%2026-11-19 19:55 ET
Revenue FY 2026 · updated 2026-11-19 16:00 ETSource ↗

Financial history

Full market history
USD 0$0USD 63$100 BUSD 125$200 BUSD 188$300 BUSD 250$400 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11USD 175.41$287 B+6.0%
  • 2026-10USD 165.41$257 B+2.4%
  • 2026-09USD 161.47$264 B-0.4%
  • 2026-08USD 162.13$265 B-4.4%
  • 2026-07USD 169.64$278 B-10.5%
  • 2026-06USD 189.62$310 B+2.1%
  • 2026-05USD 185.67$304 B-0.9%
  • 2026-04USD 187.37$307 B-5.0%
  • 2026-03USD 197.22$323 B-5.4%
  • 2026-02USD 208.45$341 B+12.3%
  • 2026-01USD 185.54$304 B+0.9%
  • 2025-12USD 183.86$301 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Shareholding as of 2026-06-30
Controlling entity
Publicly held — no controlling shareholder disclosed
Company type
Brand & Manufacturer
Insiders
0.05%
Institutions
76.35%(2,509 holders)
Free float
76.39%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →5 latest headlines12
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

AstraZeneca PLC is a global biopharmaceutical powerhouse and China's largest multinational pharmaceutical company by prescription drug revenue. Founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, the company is dual-headquartered in Cambridge, United Kingdom and Södertälje, Sweden, with FY2025 revenue of $58.74 billion (up 21% at CER) and operating profit of $14.4 billion — making it one of the fastest-growing major pharmaceutical companies globally. AstraZeneca employs approximately 80,000 people worldwide, listed on LSE, NASDAQ Stockholm, and NYSE (AZN). The company's growth has been driven by a remarkable strategic pivot from primary care toward oncology, cardiovascular-renal-metabolic (CVRM), respiratory, and rare diseases, with blockbuster drugs like Tagrisso, Imfinzi, Farxiga, and Calquence forming the foundation of a projected $80 billion revenue target by 2030.

Core Business

AstraZeneca's therapeutic portfolio spans five core areas: Oncology (37% of revenue) — anchored by Tagrisso (osimertinib, $7.4B sales), Imfinzi (durvalumab), Lynparza, and Calquence, representing one of the industry's most concentrated oncology franchises; Cardiovascular-Renal-Metabolic (CVRM, 22%) — led by Farxiga (dapagliflozin, $8.0B sales), a market-leading SGLT2 inhibitor with indications spanning diabetes, heart failure, and chronic kidney disease; Respiratory & Immunology (15%) — driven by Symbicort, Breztri, and Fasenra for severe asthma; Rare Disease (13%) — acquired through the $39 billion Alexion merger including Soliris and Ultomiris for complement-mediated disorders; and Vaccines & Immune Therapies (8%) — including the COVID-19 vaccine Vaxzevria and the RSV antibody Beyfortus. The company's R&D expenditure was approximately $14.3 billion in 2025, positioning it among the top 5 global pharmaceutical R&D spenders.

Global Presence

AstraZeneca's manufacturing and commercial footprint spans over 100 countries with 30+ manufacturing sites across 18 countries. China represents AstraZeneca's single most important geographic narrative: mainland China generated $7.3 billion in revenue (approximately 12% of global sales) and the company operates an R&D center, three manufacturing sites, and an AI-driven healthcare innovation hub in the country. In 2025, AstraZeneca announced a landmark separate listing plan for its China business on the Hong Kong Stock Exchange — an unprecedented move by a Western pharmaceutical company that signals the strategic importance of the Chinese market. The company's major manufacturing operations span Sweden (Södertälje — biologics), the UK (Macclesfield, Speke — small molecule and vaccines), the US (Gaithersburg, Frederick — biologics and cell therapy), and China (Wuxi, Taizhou — small molecule and packaging), with a cumulative global small-molecule manufacturing capacity exceeding 10 billion tablets annually.

Key Strengths

Pipeline-Driven Growth Trajectory — AstraZeneca's late-stage pipeline (20+ NMEs in Phase III) supports the company's $80 billion 2030 revenue ambition, with particular strength in antibody-drug conjugates (ADCs) and bispecific antibodies. Oncology Franchise Dominance — the combination of Tagrisso (EGFR-mutant NSCLC standard of care), Imfinzi, and Enhertu creates a durable oncology moat that is difficult for competitors to replicate. China First-Mover Advantage — no other Western pharmaceutical company has matched AstraZeneca's manufacturing investment, R&D localization, and commercial infrastructure depth in China. Portfolio Diversification — the company's balanced presence across oncology, CVRM, respiratory, and rare diseases provides revenue resilience that pure-play oncology or rare disease companies lack. Alexion Integration — the rare disease unit provides high-margin, low-competition revenue streams with Soliris/Ultomiris franchise generating over $7 billion annually. VerityRank Score of 93/100

Quick Facts

Headquarters

Cambridge, United Kingdom

Founded

1999

Employees

80,000+

Revenue

$58,739M

Market cap

$287 B

Factories

31 core manufacturing bases across 16 countries

Presence

130+ Countries
Categories

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website LSE/NYSE/STO: AZN , AstraZeneca FY & Q4 2025 Results
AstraZeneca $15B China Commitment
AZ-CSPC Obesity Deal ($1.2B Upfront)